Plasma Hydrogen Sulfide Production Capacity is Positively Associated with Post-Operative Survival in Patients Undergoing Surgical Revascularization

Objective Hydrogen sulfide (H₂S) is a gaseous signaling molecule and redox factor important for cardiovascular function. Deficiencies in its production or bioavailability are implicated in atherosclerotic disease. However, it is unknown if circulating H₂S levels differ between vasculopaths and healthy individuals, and if so, whether H₂S measurements can be used to predict surgical outcomes. Here, we examine: 1) Plasma H₂S levels in patients undergoing vascular surgery and compare these to healthy controls, and 2) Associations between H₂S levels and mortality in surgical revascularization patients.

Approach & Results Patients undergoing carotid endarterectomy, open lower extremity revascularization or leg amputation were enrolled. Peripheral blood was also collected from a matched cohort of 20 patients without peripheral or coronary artery disease. Plasma H₂S production capacity and sulfide concentration were measured using the lead acetate and monobromobimane methods, respectively. Plasma H₂S production capacity and plasma sulfide concentrations were reduced in patients with PAD (p<0.001, p=0.013 respectively). Patients that underwent surgical revascularization were divided into high versus low H₂S production capacity groups by median split. Patients in the low H₂S production group had increased probability of mortality (p=0.003). This association was robust to correction for potentially confounding variables using Cox proportional hazard models.

Conclusions Circulating H₂S levels were lower in patients with atherosclerotic disease. Patients undergoing surgical revascularization with lower H₂S production capacity, but not sulfide concentrations, had increased probability of mortality within 36 months post-surgery. This work provides insight on the role H₂S plays as a diagnostic and potential therapeutic for cardiovascular disease.

HIGHLIGHTS

• Vascular disease patients have higher plasma hydrogen sulfide levels than controls without vascular disease as measured by two distinct methods, the lead acetate hydrogen sulfide release method and the HPLC-based monobromobimane method.

• Only the lead acetate hydrogen sulfide release method robustly predicts survival after vascular surgery intervention over 35 months of follow up.

• The lead acetate release method measures non-enzymatic hydrogen sulfide release from plasma which requires iron and is catalyzed by vitamin B₆.